Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-day fosaprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in pediatric patients
2018-004844-43Phase 4Unknown
- Sponsor
- Merck & Co.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co. Primary endpoint: Percentage of participants with one or more adverse events. Status: unknown.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2018-004844-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004844-43.